Biocardia Inc (BCDA) Stock Price, Quote & News

Company Profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It is also developing an allogeneic cells therapy platform...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 226 0120

Fax: 650 631 3731

Website: www.biocardia.com

Address:

320 Soquel Way, Sunnyvale, United States

staydowngetdown Feb. 4 at 12:55 PM

$BCDA 👀

0 · Reply

Raycloser Feb. 3 at 3:18 PM

$BCDA I thought today’s announcement would have moved the needle a bit

2 · Reply

DARKP00L Feb. 3 at 1:13 PM

$BCDA 08:05 on Feb. 03 2026 BioCardia To Present Late Breaking Echocardiography Results From CardiAMP HF Trial At Technology And Heart Failure Therapeutics Meeting #tradeideas

0 · Reply

Stock_Catcher Feb. 3 at 1:04 PM

$BCDA BCDA BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)

0 · Reply

D541 Feb. 2 at 3:10 PM

$BCDA took a small exploratory position

1 · Reply

GJ_Rockabilt Jan. 30 at 1:50 PM

$BCDA No Consultation Talk Startup? Today is last day to sign up to for FREE Warrants with every Share of Cancer fighting $TPST . Acquisition in process. Do your own Due Diligence.

0 · Reply

D541 Jan. 27 at 8:12 PM

$BCDA this thing has been consolidating for half year what are we waiting for ? 4M float is explosive What's the Next catalyst ?

1 · Reply

TheUnmaker Jan. 24 at 6:58 PM

$BCDA Chart is looking better.. still a bit skeptical because we are floating in the middle of the channel.

1 · Reply

OfficialStocktwitsUser Jan. 24 at 11:17 AM

$BCDA RSI: 58.54, MACD: 0.0022 Vol: 0.07, MA20: 1.32, MA50: 1.34 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

canievas Jan. 23 at 9:25 PM

$BCDA JUST BE AWARE SHE WILL BE A MULTI DAY RUNNER. FIRST SHE WILL HIT BETWEEN $8 $10 to shake weak hands. After that we can see $10 to $15 depending the approval. After that $15 to $30. And she will settle between $20 $25 with the possibility to go higher. Be patient. Buy and hold

1 · Reply

BioCardia Cell Therapy for Ischemic Heart Failure to Progress to Formal Clinical Consultation with Japan PMDA

Dec 1, 2025, 8:30 AM EST - 2 months ago

BioCardia to Present at December 2025 CSI Focus Devices in Heart Failure Congress

Nov 24, 2025, 8:15 AM EST - 2 months ago

BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality

Nov 13, 2025, 12:11 AM EST - 2 months ago

BioCardia, Inc. (BCDA) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 4:40 PM EST - 2 months ago

BioCardia Reports Third Quarter 2025 Business Highlights and Financial Results

Nov 5, 2025, 7:29 PM EST - 3 months ago

BioCardia to Host Q3 2025 Corporate Update and Financial Results Conference Call on November 12, 2025

Oct 2, 2025, 8:00 AM EDT - 4 months ago

BioCardia Regains Compliance with Nasdaq Listing Requirements

Sep 18, 2025, 9:15 AM EDT - 4 months ago

BioCardia Announces Pricing of Up To $12 Million Public Offering

Sep 18, 2025, 7:00 AM EDT - 4 months ago

BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up

Sep 4, 2025, 9:00 AM EDT - 5 months ago

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

Aug 11, 2025, 8:37 PM EDT - 6 months ago

BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 9:15 AM EDT - 6 months ago

BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results

Aug 6, 2025, 3:18 PM EDT - 6 months ago

BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025

Aug 4, 2025, 6:00 AM EDT - 6 months ago

BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter

May 21, 2025, 8:30 AM EDT - 9 months ago

BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025

May 14, 2025, 7:40 PM EDT - 9 months ago

BioCardia, Inc. (BCDA) Q1 2025 Earnings Call Transcript

May 14, 2025, 4:05 PM EDT - 9 months ago

BioCardia Reports First Quarter 2025 Business Highlights and Financial Results

May 9, 2025, 4:28 PM EDT - 9 months ago

BioCardia to Host Q1 2025 Corporate Update and Financial Results Conference Call on May 14, 2025

Apr 11, 2025, 9:15 AM EDT - 10 months ago

BioCardia Initiates Patient Enrollment at Emory University School of Medicine for Ongoing CardiAMP HF II Pivotal Study

Mar 31, 2025, 11:30 PM EDT - 11 months ago

BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 1:39 PM EDT - 11 months ago

BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today

Mar 26, 2025, 4:30 PM EDT - 11 months ago

BioCardia Reports 2024 Business Highlights and Financial Results

Mar 21, 2025, 8:30 AM EDT - 11 months ago

BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025

Mar 10, 2025, 9:15 AM EDT - 11 months ago

BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

Feb 27, 2025, 9:15 AM EST - 1 year ago

BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions

Feb 13, 2025, 8:30 AM EST - 1 year ago

BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF)

Jan 27, 2025, 9:15 AM EST - 1 year ago

BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions

Dec 4, 2024, 8:30 AM EST - 1 year ago

BioCardia Announces Positive Consultation with Japan PMDA on CardiAMP Cell Therapy for Ischemic Heart Failure

Nov 13, 2024, 7:49 PM EST - 1 year ago

BioCardia, Inc. (BCDA) Q3 2024 Earnings Call Transcript

Sep 18, 2024, 8:30 AM EDT - 1 year ago

BioCardia Regains Full Compliance with Nasdaq Listing Requirements

Sep 9, 2024, 4:05 PM EDT - 1 year ago

BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Aug 29, 2024, 8:30 AM EDT - 1 year ago

BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family

Aug 21, 2024, 7:00 AM EDT - 1 year ago

FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment

Aug 13, 2024, 7:53 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 4:30 PM EDT - 1 year ago

BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results

Jul 17, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application

Jun 7, 2024, 7:00 AM EDT - 1 year ago

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach

May 21, 2024, 5:00 PM EDT - 1 year ago

BioCardia Announces Reverse Stock Split

May 14, 2024, 11:00 PM EDT - 1 year ago

BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript

May 14, 2024, 4:02 PM EDT - 1 year ago

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

May 9, 2024, 7:00 AM EDT - 1 year ago

BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024

May 1, 2024, 7:00 AM EDT - 1 year ago

BioCardia's CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes

Apr 25, 2024, 9:00 AM EDT - 1 year ago

BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort

Mar 27, 2024, 8:00 PM EDT - 2 years ago

BioCardia, Inc. (BCDA) Q4 2023 Earnings Call Transcript

Mar 27, 2024, 4:00 PM EDT - 2 years ago

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results

Mar 20, 2024, 7:00 AM EDT - 2 years ago

BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024

Mar 13, 2024, 7:00 AM EDT - 2 years ago

BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

Mar 12, 2024, 7:00 AM EDT - 2 years ago

BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

Mar 4, 2024, 8:00 AM EST - 2 years ago

BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

Feb 8, 2024, 7:00 AM EST - 2 years ago

BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA

staydowngetdown Feb. 4 at 12:55 PM

$BCDA 👀

0 · Reply

Raycloser Feb. 3 at 3:18 PM

$BCDA I thought today’s announcement would have moved the needle a bit

2 · Reply

DARKP00L Feb. 3 at 1:13 PM

$BCDA 08:05 on Feb. 03 2026 BioCardia To Present Late Breaking Echocardiography Results From CardiAMP HF Trial At Technology And Heart Failure Therapeutics Meeting #tradeideas

0 · Reply

Stock_Catcher Feb. 3 at 1:04 PM

$BCDA BCDA BioCardia Announces Late Breaking Echocardiography Results from the CardiAMP HF Trial to be Presented at Technology and Heart Failure Therapeutics (THT)

0 · Reply

D541 Feb. 2 at 3:10 PM

$BCDA took a small exploratory position

1 · Reply

GJ_Rockabilt Jan. 30 at 1:50 PM

$BCDA No Consultation Talk Startup? Today is last day to sign up to for FREE Warrants with every Share of Cancer fighting $TPST . Acquisition in process. Do your own Due Diligence.

0 · Reply

D541 Jan. 27 at 8:12 PM

$BCDA this thing has been consolidating for half year what are we waiting for ? 4M float is explosive What's the Next catalyst ?

1 · Reply

TheUnmaker Jan. 24 at 6:58 PM

$BCDA Chart is looking better.. still a bit skeptical because we are floating in the middle of the channel.

1 · Reply

OfficialStocktwitsUser Jan. 24 at 11:17 AM

0 · Reply

canievas Jan. 23 at 9:25 PM

1 · Reply

Raycloser Jan. 22 at 4:50 AM

$BCDA why does Altman buy so little each time?

2 · Reply

CEOBuysDisclosures Jan. 22 at 12:05 AM

$BCDA CEO purchased 900 shares at $1.33 for a total of $1,194. Altman Peter now owns 268,866 shares. https://ceo-buys.com

0 · Reply

TheUnmaker Jan. 10 at 12:39 PM

$TNXP $HSCS $BCDA just starting to heat up.

1 · Reply

GJ_Rockabilt Jan. 10 at 12:59 AM

$BCDA We have to guess what the guessed News was they guessed would be in December and now must guess when the guessed News will be Released I guess.

2 · Reply

canievas Jan. 9 at 8:50 PM

$BCDA keep loading here I’m a long term investor here 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀

0 · Reply

mankind1 Jan. 8 at 4:53 PM

$BCDA quiet...too quiet

2 · Reply

BillionerOfKing Jan. 7 at 1:50 PM

$BCDA Current Stock Price: $1.27

0 · Reply

NineLinesCat Jan. 5 at 12:59 AM

$BCDA ...Happy New Year to all bcda traders. First full week of trading. Let's get news and lets get busy...

1 · Reply

chris_stocks Dec. 31 at 10:09 PM

$BCDA they were supposed to meet with the FDA in December to seek a pathway toward approval. December is over. Has anyone heard anything about it? When will they hear from Japan?

0 · Reply

GJ_Rockabilt Dec. 30 at 2:33 PM

$BCDA PT Analyst Forecasts range from $6.00-$25.00. Average BCDA Price Target is $15.50. Impending News.

1 · Reply

GJ_Rockabilt Dec. 29 at 11:31 PM

$BCDA My idea : 1. BCDA will decide to find more Strategic Allies by reaching out, phone call after phone call. 2. BCDA must demonstrate payer interest, manufacturing readiness, and early access programs.

0 · Reply

GJ_Rockabilt Dec. 29 at 10:08 PM

$BCDA

0 · Reply

Market Cap	13.05M
Revenue (ttm)	60,000.00
Net Income (ttm)	-7.95M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-13,250.00%
Debt to Equity Ratio	0.00

Volume	49,000
Avg Vol	78,828
Day's Range	N/A - N/A
Shares Out	10.61M
Stochastic %K	0%
Beta	0.56
Analysts	Sell
Price Target	$15.50